Introduction
The protozoan parasitaemia that characterizes malaria, results from infection with Plasmodium spp., which is inoculated by the female Anopheles mosquito -usually between dusk and dawn.' Transmission occurs over much of the globe; one estimate is that 46% of the world's human population lives in this area, and a recent WHO guesstimate indicates that 300 million individuals (90% of them in tropical Africa) are infected, of whom 2 million (1.2 million in Africa) die annually" 2 (most belonging to the under 5 year old group).
From an hepatic viewpoint, it is important to appreciate that whereas P. falciparum infection (the severe form of the disease and the only one to cause acute mortality) and P. malariae directly utilize the hepatocyte during their life-cycle within Homo sapiens, P. vivax and P. ovale also undergo a dormant phase (the hypnozoite stage) in these cells, which allows recrudescence(s) to occur." [3] [4] [5] The question as to whether malaria is a precursor of hepatitis, and later cirrhosis, is one which has perplexed physicians, including hepatologists, for many years. In 1898, Dr '6 In an indigenous population in an area of high transmission, RE changes therefore predominate; hepatocyte changes (which are minimal) consist of lipofuscin and occasionally haemosiderin (malaria pigment) deposition, fat-droplet formation, mitochondrial swelling, and microvillus loss. Research has largely concentrated on the possibility of a sporozoite vaccine;45'46 other investigators have sought a safe and effective merozoite or gametocyte preparation. Induction ofprotective immunity is made difficult by phenotypic/sequential antigenic variation, and antigenic diversity. Only in the hepatocyte cycle (see above) is there a possibility of inducing a cytotoxic lymphocyte response.5 Host factors, which must be crucially important, leading to resistance to severe complicated infection are slowly being unravelled.47
Conclusions
Few, if any, would now give credence to early work that purported to invoke hepatitis and/or cirrhosis as long-term sequelae of Plasmodium spp. infection (see above). In the light of available data, however, the following conclusions seem justified: 1. Hepatocyte involvement, which is crucial to the life-cycle of Plasmodium spp., does not produce significant clinical disease; 
